Hook & thesis
Hims & Hers Health (HIMS) has been punished for margin compression, a costly acquisition and a convertible debt package. That reaction is understandable, but it's also overdone in the price: the company guided 2026 revenue to $2.8-3.0 billion, reported steady revenue growth in Q1, and is executing on GLP-1 distribution with meaningful order activity. For traders willing to accept volatility, the recent pullback creates an asymmetric risk/reward where disciplined position sizing and a clear stop can buy exposure to both operational recovery and an expanding addressable market.
Why the market should care
Hims & Hers runs a direct-to-consumer telehealth platform covering mental health, sexual health, dermatology and primary care. Most importantly for the next 12-24 months is its role in weight-loss therapeutics distribution: the company is actively shipping GLP-1s (including Wegovy via its Novo Nordisk partnership) and has fulfilled over 125,000 Wegovy shipments. That operational traction matters because employers are signaling changes to GLP-1 coverage in 2027. If coverage tightens, patients will increasingly seek telehealth channels to access care and prescriptions - a channel Hims already operates at scale.
Snapshot of the business and recent results
On the top line, Hims delivered Q1 revenue of $608.1 million, up 4% year-over-year, and raised full-year guidance to $2.8-3.0 billion. That puts the company in the multi-billion revenue club with an enterprise value around $9.12 billion. Despite revenue growth, profitability has deteriorated: the company swung to a $92.1 million net loss from a $49.5 million profit a year earlier, and adjusted EBITDA fell sharply. Gross margins compressed from 73% to 65% as the business shifted from higher-margin compounded GLP-1 fulfillment to lower-margin branded weight-loss products and increased spend on international expansion, AI and diagnostics.
Key numbers you should know
- Market cap: roughly $8.37 billion
- Enterprise value: roughly $9.12 billion
- Q1 revenue: $608.1 million (+4% YoY)
- 2026 revenue guidance: $2.8-3.0 billion
- Free cash flow (most recent): ~$66.9 million
- Gross margin decline: 73% to 65% quarter-over-quarter
- Convertible debt raise: $350 million (zero-coupon) to help fund a $1.15 billion acquisition of an Australian telehealth business
- Short interest: elevated (reports flagged ~31.4% at one point and persistent high short volume), meaning a crowded negative bet exists
Valuation framing
Hims now trades at a trailing price-to-sales multiple of 3.53x, according to recent market ratios. Using the midpoint of management's 2026 revenue guidance ($2.9 billion), the market cap implies a forward price-to-sales closer to ~2.9x. That forward multiple is not cheap on an absolute basis for a health-services business, but it becomes more palatable when you factor in (a) the structural growth opportunity in telehealth and weight-loss therapeutics, (b) diversified product lines beyond GLP-1s, and (c) international expansion via the Eucalyptus acquisition. The market’s current discount appears driven more by skepticism around margin sustainability and balance-sheet dilution from the convertible debt than by top-line risk alone.
Trade idea - actionable plan
I’m initiating a tactical long with a clearly defined entry, stop and target. This is a swing trade meant to capture a re-rating as momentum and clearer margin signals emerge.
- Trade direction: Long
- Entry price: $36.00
- Stop loss: $31.00
- Target price: $52.00
- Horizon: mid term (45 trading days) - this allows time for a technical recovery, sentiment normalization, or one earnings/operational update to re-price the stock.
Why this sizing and horizon? The entry sits near current prices and short-term moving averages (10/21-day EMAs are supportive), so the first objective is to catch a mean-reversion rally. The stop at $31 caps downside to a manageable loss if the market reasserts that margins or dilution fears are unresolved. The $52 target is a pragmatic re-rating toward a more normalized multiple - it’s still well below the 52-week high of $70.43 but captures a meaningful recovery (~44% from $36) if revenue execution continues and headline risk stabilizes.
Catalysts that could drive the trade
- Continued GLP-1 fulfillment growth - the company already reported over 125,000 Wegovy shipments; continued cadence would validate the revenue upside.
- Operational cadence improvements - stabilization or reversal of gross-margin compression would materially change the earnings outlook and sentiment.
- Early synergies from the Eucalyptus acquisition - any sign that international revenue ramps faster than modeled would increase conviction.
- Reduce convert uncertainty - clarity on the $350 million convertible structure (conversion mechanics, likelihood of dilution) or an opportunistic buyback/tender would remove a headline overhang.
- Macro/healthcare tailwinds - if employers announce tighter GLP-1 coverage for 2027, direct-to-consumer channels should see an incremental demand tailwind.
Risks and counterarguments
This trade is not without material risks. Below are the principal downside scenarios and a counterargument to the bullish thesis.
- Margin risk: The company has already shown gross-margin compression from 73% to 65%. If Hims fails to restore margins (or if branded product mix remains lower-margin), adjusted EBITDA could stay depressed and the market will keep multiple contraction pressure in place.
- Balance-sheet/dilution risk: The $350 million zero-coupon convertible debt materially raises dilution or refinancing risk. If markets change and debt converts into equity at unattractive terms, existing shareholders will feel the dilution and the stock could reprice lower.
- Execution in international expansion: The $1.15 billion acquisition of Eucalyptus is strategic but expensive. Cross-border integration missteps or slower-than-expected monetization would weigh on results.
- Regulatory and product risk: The weight-loss space faces regulatory scrutiny and shifting reimbursement policy. Any restrictions on GLP-1 prescribing, distribution, or telehealth access would directly hit Hims’ growth runway.
- Sentiment and high short interest: High short interest has driven volatile moves; while that can amplify rallies, it also accelerates downside if a new negative catalyst appears. Short-volume flow has been persistently large, increasing trading risk.
Counterargument: Critics will say the company is trading like a growth name with a shrinking margin profile and a levered balance sheet - and that’s fair. If Hims cannot demonstrate margin recovery or if its GLP-1 strategy is more volume than value (low margin, high churn), the multiple is likely to compress further. Those outcomes would invalidate the trade and justify the stop.
What would change my mind
I will reassess the bullish view if any of the following occur: (a) management provides new forward guidance that materially cuts revenue expectations or keeps adjusted EBITDA guidance below current ranges, (b) the convertible debt converts in a dilutive manner without offsetting accretive investments, or (c) GLP-1 shipments stall and new patient acquisition economics degrade. Conversely, a clearer path to margin stabilization, accelerating international revenue from Eucalyptus, or a meaningful reduction in balance-sheet uncertainty would strengthen the bullish case and prompt me to consider a larger position.
Position management and exit plan
This is a trade-sized idea, not a full conviction portfolio overweight. Enter near $36.00, trail the stop to breakeven once the position gains 15-20%, and consider trimming into strength if the stock approaches the target. If a positive catalyst appears (e.g., margin improvement, stronger-than-expected GLP-1 volumes, or constructive commentary on the convertible), re-evaluate to potentially convert this into a longer-term position with an updated stop anchored on revised fundamentals.
Bottom line: the market is fixated on margin pain and balance-sheet headlines, but Hims still has revenue momentum, clear operational proof points in GLP-1 fulfillment, and strategic expansion that justify a contrarian, risk-managed long. Treat this as a tactical swing: defined entry at $36.00, a firm stop at $31.00 and a realistic target of $52.00 over ~45 trading days.